ISRCTN47562898已完成不适用
Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older people with Down's syndrome, with and without dementia
King's College London (UK)0 个研究点目标入组 180 人开始时间: 2005年5月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •People with Down's syndrome over the age of 40 and/or dementia
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older people with Down’s syndrome, with and without dementia - Memantine in people with Down's syndromeEUCTR2005-000381-39-GBKing's College London180
已完成
2 期
Memantine effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N2Vice chancellor for research, Mazandaran University of Medical Sciences50
已完成
4 期
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum DisordersAutism Spectrum DisordersNCT01333865Massachusetts General Hospital25
Unknown
不适用
Memantine and Down's SyndromeDown's SyndromeLearning DisabilitiesDementiaNCT00240760King's College London180
已完成
4 期
Bioequivalence study of 20 mg memantine hydrochloride film-coated tablets in healthy Thai volunteersCompany has manufactured a new formulation of memantine hydrochloride film-coated tablets 20 mg for which this study has been planned to evaluate the pharmacokinetics of the new formulation.TCTR20161103001Research and Development28